family with sequence similarity 53 member BGenealiases: KIAA0140 · bA12J10.2 · smp
Q-omics provides the consensus-scored FAM53B profile across patient tissues and cancer cell-line models. FAM53B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM53B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FAM53B RNA expression shows 19,091 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where FAM53B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM53B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM53B survival associations across molecular data types. FAM53B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM53B RNA expression–survival associations across cancer types. High FAM53B expression shows unfavorable associations in ACC, but favorable associations in HNSC, KIRC, STAD, PAAD and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM53B RNA expression.
This table summarizes FAM53B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM53B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM53B shows lower tumor expression in THCA, LUAD and BLCA and higher tumor expression in KIRC, LIHC and STAD. The KIRC box plot shows higher FAM53B RNA expression in tumor versus normal tissue (log2 FC = +0.895, t-test p < 0.001).
This table shows molecular features associated with FAM53B in patient tissues and cancer cell lines. In patient samples, FAM53B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM53B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
